Pfizer, GSK, GEA and Vertex share insights and increase knowledge on advances and challenges in the continuous processing field
28 May 2014 – Two leading global companies, pharmaceutical contract development and manufacturing organisation (CDMO) Aesica and speciality excipient and coating company, Colorcon, are today co-hosting a ground breaking workshop at the Royal College of Physicians in London. This key industry event is focused on major advances and challenges in the emerging field of continuous processing. The workshop will bring together leading experts from the pharmaceutical sector to discuss this potentially transformational approach and explore its implications for the development and manufacture of solid oral dosage forms.
In addition to Aesica and Colorcon, representatives from AstraZeneca, Pfizer, GSK, GEA Process Engineering and Vertex Pharmaceuticals will speak on a multitude of continuous processing related topics. The themes range from:
• Multipurpose approaches for solid oral dose manufacture, including both rapid development paradigms and continuous process design
• The speed of the process – from powder to a coated tablet in less than one hour
• Recent advances in continuous film coating technologies
• Industrial challenges and opportunities in continuous processing for tablet manufacturing
• Continuous drug product manufacturing for breakthrough therapies
Jeremy Drummond, Sales Director, Finished Dose at Aesica commented: “We are delighted to be at the joint forefront of bringing together key industry experts in continuous processing, from across the pharmaceutical industry sector, in what is designed to be a highly informative forum for discussion, understanding and the sharing of knowledge. The workshop will provide authoritative and stimulating insights from within the pharmaceutical industry to aid and assist the drawing up of the very best framework that will oversee this new, growing and exciting field.”
He adds “Continuous processing is fast emerging as a real asset to solid oral dosage manufacture. Consequently, we are especially pleased that this event, which we are co-hosting with Colorcon, has brought together such a wide range of specialists from leading pharmaceuticals companies, as well as our technical centers. This is set to ensure that it will be a very informative affair for all concerned.”
Dr Ali Rajabi-Siahboomi, VP & Chief Scientific Officer at Colorcon shared his insight on the event: “As Quality by Design (QbD) initiatives are progressing in the pharmaceutical industry, continuous processing and manufacturing of drug products are becoming more acceptable and realistic. This highly interactive workshop provides unique opportunities for a timely and open dialogue across industry stakeholders. Our goal is to provide attendees with a forum to discuss practical applications that aid in the development and manufacture of solid oral dosage forms. The event presents a unique opportunity to discuss real and perceived hurdles for successful implementation and create clarity on the benefits of continuous processing for pharmaceuticals.”
About Aesica:
Aesica supplies contract development and contract manufacturing services for finished products and active pharmaceutical ingredients to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.
The uniqueness of Aesica lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. It is this all-encompassing offering combined with its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.
• Aesica is one of the UK’s fastest growing companies and over the last five years has more than trebled its turnover
• The company currently employs approximately 1,300 people
• In addition to its headquarters in Newcastle upon Tyne, UK, Aesica has development and manufacturing sites across Europe including Cramlington, Nottingham and Queenborough in the UK, as well as sites in Monheim and Zwickau in Germany and Pianezza in Italy
• The vision of Aesica is to become the number one supplier of APIs and formulated products to the pharmaceutical industry
• Aesica is a portfolio company of Silverfleet Capital, one of the leading European mid-market private equity firms, which invested in the business in October 2011
For more information, visit www.aesica-pharma.com
About Colorcon:
Colorcon is a world leader in the development, supply and technical support of formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry.
Colorcon has 18 technical service laboratories globally and more than 1200 employees exclusively dedicated to its customer base. Our best-in-class products and technologies are complemented by our extensive application data and value-added services to support all phases of solid oral dose design and development.
Our focus on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice. That reputation is based on the superior product quality, unparalleled technical support, and extensive regulatory assistance we provide.
Colorcon works together with Dow Pharma & Food Solutions through the Controlled Release Alliance to bring joint resource to accelerate pharmaceutical product development efforts for controlled release and reach markets throughout the world. Colorcon has exclusive, global sales and distribution rights for Dow Pharma & Food Solutions' products used in controlled release pharmaceutical applications.
For more information, visit www.colorcon.com
For Aesica media enquiries, please contact Tristan Jervis or Alex Heeley on: +44 (0) 207 203 6740 or e-mail: t.jervis@defacto.com. For Colorcon media enquiries, please contact: Richard Hayhurst on : +44 7711 821527 or email Richard@richardhayhurstassociates.com
Help employers find you! Check out all the jobs and post your resume.
